MedTrace Logo

Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis

NCT06477237 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2024-06-27

No results posted yet for this study

Summary

This is a multicenter, randomized, double-blind, placebo-controlled, phase III clinical study which is designed to determine the efficacy, safety, immunogenicity and pharmacokinetics, and pharmacodynamics of HB0017 Injection in the treatment of moderate to severe plaque psoriasis in adults.

Conditions

Interventions

BIOLOGICAL

HB0017 Q4W

HB0017 at W0,1,2,4,8+HB0017Q4W

BIOLOGICAL

HB0017 Q8W

HB0017 at W0,1,2,4,8+HB0017Q8W

BIOLOGICAL

placebo

placebo at W0,1,2,4,8+HB0017Q4W

Sponsors & Collaborators

  • Huabo Biopharm Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Jianzhong Zhang, MD · Peking University People's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-01
Primary Completion
2024-08-31
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06477237 on ClinicalTrials.gov